CN108883168A - 使用疫苗治疗癌症或皮肤病变的方法和组合物 - Google Patents

使用疫苗治疗癌症或皮肤病变的方法和组合物 Download PDF

Info

Publication number
CN108883168A
CN108883168A CN201780016785.3A CN201780016785A CN108883168A CN 108883168 A CN108883168 A CN 108883168A CN 201780016785 A CN201780016785 A CN 201780016785A CN 108883168 A CN108883168 A CN 108883168A
Authority
CN
China
Prior art keywords
hpv
dose
vaccine
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780016785.3A
Other languages
English (en)
Chinese (zh)
Inventor
蒂姆·艾恩尼德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weekes Harper Is A LLC
Original Assignee
Weekes Harper Is A LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weekes Harper Is A LLC filed Critical Weekes Harper Is A LLC
Publication of CN108883168A publication Critical patent/CN108883168A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201780016785.3A 2016-02-27 2017-02-24 使用疫苗治疗癌症或皮肤病变的方法和组合物 Pending CN108883168A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US62/300,785 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US62/328,487 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US62/338,183 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US62/444,576 2017-01-10
US201762455434P 2017-02-06 2017-02-06
US62/455,434 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
CN108883168A true CN108883168A (zh) 2018-11-23

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780016785.3A Pending CN108883168A (zh) 2016-02-27 2017-02-24 使用疫苗治疗癌症或皮肤病变的方法和组合物

Country Status (16)

Country Link
EP (1) EP3419661A4 (enExample)
JP (3) JP2019506435A (enExample)
KR (1) KR102873848B1 (enExample)
CN (1) CN108883168A (enExample)
AU (1) AU2017223970B2 (enExample)
BR (1) BR112018067550A2 (enExample)
CA (1) CA3015519A1 (enExample)
CL (1) CL2018002438A1 (enExample)
CO (1) CO2018009205A2 (enExample)
HK (1) HK1256935A1 (enExample)
IL (1) IL261340B2 (enExample)
MX (1) MX2018010338A (enExample)
MY (1) MY194694A (enExample)
SG (1) SG11201807080UA (enExample)
WO (1) WO2017147475A1 (enExample)
ZA (1) ZA201805679B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302098A (en) * 2020-10-12 2023-06-01 Hpvvax Llc The composition and method for treating cancer using a vaccine as a first active therapeutic ingredient in combination with a second active ingredient
KR20250089555A (ko) * 2022-10-31 2025-06-18 파이로자스 인크 면역요법 조성물 및 사용 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890160A (zh) * 2009-04-28 2010-11-24 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
CN102481378A (zh) * 2009-04-13 2012-05-30 法国健康和医学研究院 Hpv颗粒及其用途
CN102497880A (zh) * 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP2014516075A (ja) * 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
CN104203270A (zh) * 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3054994A4 (en) * 2013-10-13 2017-10-11 The Board of Trustees of the University of Arkansas Human papilloma virus therapeutic vaccine
AU2015204503B2 (en) * 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
AU2015335652B2 (en) * 2014-10-24 2020-07-02 Hpvvax, Llc. Cancer and skin lesion treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481378A (zh) * 2009-04-13 2012-05-30 法国健康和医学研究院 Hpv颗粒及其用途
CN101890160A (zh) * 2009-04-28 2010-11-24 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
CN102497880A (zh) * 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNA TADDIO等: "A randomized controlled trial of analgesia during vaccination in adults", 《VACCINE 》 *
明日科学网: "人类乳突病毒疫苗成功治疗皮肤癌", 《中国肿瘤临床与康复》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021013069A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白

Also Published As

Publication number Publication date
MY194694A (en) 2022-12-15
BR112018067550A2 (pt) 2019-10-01
EP3419661A4 (en) 2019-10-23
AU2017223970B2 (en) 2022-01-27
AU2017223970A1 (en) 2018-09-13
IL261340B2 (en) 2023-07-01
JP7732784B2 (ja) 2025-09-02
SG11201807080UA (en) 2018-09-27
CL2018002438A1 (es) 2019-01-04
CO2018009205A2 (es) 2018-09-20
MX2018010338A (es) 2018-11-09
IL261340A (en) 2018-11-29
IL261340B1 (en) 2023-03-01
JP2019506435A (ja) 2019-03-07
WO2017147475A1 (en) 2017-08-31
JP2023110038A (ja) 2023-08-08
KR20180112043A (ko) 2018-10-11
HK1256935A1 (zh) 2019-10-04
KR102873848B1 (ko) 2025-10-17
JP2021155448A (ja) 2021-10-07
EP3419661A1 (en) 2019-01-02
ZA201805679B (en) 2019-11-27
CA3015519A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
EP3273955B1 (en) Treatment of respiratory diseases
JP2023110038A (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
CA3219273A1 (en) Use of 5-nitro-8-hydroxyquinoline
US10799574B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
AU2021360676B2 (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
KR20080048542A (ko) 인간 유두종 바이러스에 저항하는 약제 제조를 위한노카르디아 루브라 세포벽 골격의 용도
WO2021181279A1 (en) Compositions and methods for treating covid-19 infections and/or symptoms thereof
JP6663438B2 (ja) 癌および皮膚病変の治療
WO2022264097A1 (en) Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита
US20230310467A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
HK40058742A (en) Treatment of respiratory diseases
HK40059876A (en) Treatment of respiratory diseases
WO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви
HK1241898A1 (en) Cancer and skin lesion treatment
HK1100533B (en) Use of nocardia rubra cell wall skeleton to produce medicaments for resisting human papilloma virus hpv

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256935

Country of ref document: HK